Trinity Biotech (TRIB) Stock Statistics & Valuation Metrics

Trinity Biotech has a market cap or net worth of $6.90M. The enterprise value is $138.87M.

Trinity Biotech has 20,250,870 shares outstanding. The number of shares has decreased by -2.65% in one year.

Trinity Biotech’s return on equity (ROE) is 0.52 and return on invested capital (ROIC) is -15.27%.

The current PE Ratio of Trinity Biotech is ―. Trinity Biotech’s PEG ratio is -0.03.

In the last 12 months, Trinity Biotech had revenue of 43.78M and earned -37.38M in profits. Earnings per share was -2.00.

In the last 12 months, operating cash flow was -6.26M and capital expenditures -88.26K, giving a free cash flow of -6.34M billion.

Trinity Biotech pays an annual dividend of $1.1, resulting in a dividend yield of ―

Trinity Biotech upcoming earnings date is Sep 3, 2026, TBA (Confirmed).

Trinity Biotech as a current ratio of 0.25, with Debt / Equity ratio of -191.69%

In the past 12 months, Trinity Biotech has paid 199.00K in taxes.

Trinity Biotech EV to EBITDA ratio is -6.90, with an EV/FCF ratio of -12.14.

Trinity Biotech has $5.14M in cash and marketable securities with $137.98M in debt, giving a net cash position of -$132.84M billion.

Gross margin is 35.40%, with operating margin of -26.07%, and net profit margin of -85.36%.

The average price target for Trinity Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―